Blue Jet Healthcare Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Blue Jet Healthcare Ltd filed with BSE on 07 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Blue Jet Healthcare reported Q1 FY27 revenue of INR293 crores, up 25% sequentially, with operating EBITDA margin of 33.5% versus 30.4% in the prior quarter. Management attributed the improvement to stronger PI/API vertical performance following normalization of customer inventory, while contrast media revenue declined due to goods-in-transit recognition delays from container availability and geopolitical disruptions. The company also detailed progress on its Vizag expansion, Unit 3 backward integration project, and a new Hyderabad R&D center expected to become operational during the month.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Revenue from operations: INR293 crores (Q1 FY27)
p. 3
“During the quarter, we reported revenue from operations of INR293 crores and an EBITDA of INR98 crores, reflecting healthy sequential improvement.”
Shiven Arora, page 3 of the filed PDF · View the filing
EBITDA: INR98 crores (Q1 FY27)
p. 3
“During the quarter, we reported revenue from operations of INR293 crores and an EBITDA of INR98 crores, reflecting healthy sequential improvement.”
Shiven Arora, page 3 of the filed PDF · View the filing
Turnover growth: 25% (Q1 FY27 vs Q4 FY26)
p. 6
“During this quarter, we reported a turnover of INR293 crores, an increase of 25% over previous quarter.”
Ganesh Karuppannan, page 6 of the filed PDF · View the filing
Gross margin: 53% (Q1 FY27)
p. 6
“Our reported gross margin at 53% is a reduction of 3% over previous quarter”
Ganesh Karuppannan, page 6 of the filed PDF · View the filing
Operating EBITDA margin: 33.5% (Q1 FY27)
p. 6
“reported operating EBITDA is 33.5% compared to 30.4% in the previous quarter, an increase of 3%.”
Ganesh Karuppannan, page 6 of the filed PDF · View the filing
Profit after tax margin: 26.7% (Q1 FY27)
p. 6
“Our profit after tax for the quarter is 26.7% against 27.4% in the previous quarter, a reduction of 0.7%.”
Ganesh Karuppannan, page 6 of the filed PDF · View the filing
Goods in transit increase: INR30-odd crores (Q1 FY27)
p. 7
“Closing cut-off, what you call goods in transit is higher by INR30-odd crores compared to opening cut off.”
Ganesh Karuppannan, page 7 of the filed PDF · View the filing
Investment in Unit 3 (Mahad) project: INR210 crores
p. 5
“We have invested already about INR210 crores on this project with a further INR40 crores committed in the next couple of months to complete this phase.”
VK Singh, page 5 of the filed PDF · View the filing
Plant utilization (contrast media): 70-odd percent (Q1 FY27)
p. 7
“That we are at 70-odd percent steady.”
Ganesh Karuppannan, page 7 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Vizag Phase 1 capex — approximately INR1,000 crores · next 3 years
stated firmly by VK Singh
p. 5
“This phase represents an investment of approximately INR1,000 crores over the next 3 years.”
VK Singh, page 5 of the filed PDF · View the filing
Unit 3 backward integration commercial contribution — second half of FY27
stated firmly by Shiven Arora
p. 4
“At Unit 3, backward integration project continues to progress well and remains on-track with commercial contribution expected during the second half of FY27.”
Shiven Arora, page 4 of the filed PDF · View the filing
Unit 3 commissioning — later this calendar year
stated firmly by VK Singh
p. 5
“Once commissioned later this calendar year and here, I must emphasize that earlier, we had guided H2, but I think we are slightly ahead of schedule here.”
VK Singh, page 5 of the filed PDF · View the filing
Hyderabad R&D center operational date — current month
stated firmly by Shiven Arora
p. 4
“Our Hyderabad R&D center also remains on-track and is expected to become operational during the current month.”
Shiven Arora, page 4 of the filed PDF · View the filing
Contrast Media candidate launches — 3 candidates · FY27
stated firmly by VK Singh
p. 6
“During FY27, we expect to launch 3 candidates within the Contrast Media segment alongside initiating pilot activities for a new high-intensity sweetener.”
VK Singh, page 6 of the filed PDF · View the filing
Iodinated Contrast Media commercial batches — end of Q2 or beginning of Q3
stated conditionally by Ganesh Karuppannan
p. 7
“We hope to start the commercial batches very shortly. We would see some positive trend either by end of Q2 or beginning of Q3.”
Ganesh Karuppannan, page 7 of the filed PDF · View the filing
PI/API revenue visibility — next 3 or 4 quarters
stated firmly by VK Singh
p. 8
“So at least for the next 3 or 4 quarters, I think we have very good visibility.”
VK Singh, page 8 of the filed PDF · View the filing
NCE opportunities fructifying — 2 of the high conviction opportunities
stated as an aspiration by VK Singh
p. 10
“We feel that at least 2 of these opportunities, the high conviction opportunities, which are shaping up well, should fructify in the time frame that you have mentioned, how large they would be we should neither guess nor guide at this moment.”
VK Singh, page 10 of the filed PDF · View the filing
Asset turn ramp-up — industry norm · FY31 or FY32
stated conditionally by Ganesh Karuppannan
p. 13
“Based on the investments and based on the products we are looking at, we expect the industry norm whatever we will we will be achieving.”
Ganesh Karuppannan, page 13 of the filed PDF · View the filing
Vizag commercialization start — end FY29 to FY30
stated firmly by Ganesh Karuppannan
p. 13
“See, today, if you look at our significant capex is going to be in Vizag and commercialization would start from end FY29 to FY30.”
Ganesh Karuppannan, page 13 of the filed PDF · View the filing
Long-term ambition in complex chemistry — globally recognized partner · medium and long-term
stated as an aspiration by Shiven Arora
p. 4
“Our long-term ambition is to establish Blue Jet as a globally recognized partner in complex chemistry combining scientific innovation, manufacturing excellence and deep customer collaboration to create sustainable value for our stakeholders.”
Shiven Arora, page 4 of the filed PDF · View the filing
FY27 capex guidance — INR400 crores · FY27
stated firmly by Ganesh Karuppannan
p. 16
“At the company level, it will be similar amount.”
Ganesh Karuppannan, page 16 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management quantified the goods-in-transit delay and confirmed steady plant utilization despite lower recognized sales.
Answered by Ganesh Karuppannan
Asked by Samitinjoy: How much of the contrast media revenue shortfall will be recognized in Q2, and what are utilization levels?
p. 7
“But in other words, the goods in transit is higher by INR30 crores. And in a nutshell, that is the sales we would be recognizing in the next quarter.”
Ganesh Karuppannan, page 7 of the filed PDF · View the filing
Management said both secular market growth and a strong order book support the segment's visibility.
Answered by VK Singh
Asked by Sanjesh: Is the surge in PI/API revenue sustainable or volatile like before?
p. 8
“So there is clear secular growth at the front end.”
VK Singh, page 8 of the filed PDF · View the filing
Management said no price increase clause had been triggered yet, and pricing changes are being evaluated case by case against rupee devaluation offsets.
Answered by Ganesh Karuppannan
Asked by Sanjesh: How much price increase is being passed through given raw material cost pressure?
p. 9
“See, there is no price increase clause which we have triggered in this quarter.”
Ganesh Karuppannan, page 9 of the filed PDF · View the filing
Management said it was premature to give a number until commercialization ramps up, expecting industry-standard asset turns eventually.
Answered by Ganesh Karuppannan
Asked by Manan Vandur: What should long-term asset turn look like given the large Vizag capex?
p. 13
“So, it is true maybe not appropriate to put a number at this stage because to achieve the ramp-up, maybe one would actually look at FY31 or FY32.”
Ganesh Karuppannan, page 13 of the filed PDF · View the filing
Management said they are only intermediate suppliers, not experts on the molecule's clinical profile, and remain confident in their order book across US, Europe and Japan.
Answered by VK Singh
Asked by Saket Saurabh: Could Merck's Lipfendra become a commercial competitor to the cholesterol-lowering molecule Blue Jet supplies for?
p. 13
“All that we are concerned with is the visibility that we have and our order book, which is all very robust.”
VK Singh, page 13 of the filed PDF · View the filing
Management clarified Mahad is for backward-integrated intermediate production, not end-product contrast media, with potential future third-party sales.
Answered by VK Singh
Asked by Viraj: What is the outlook for the Mahad capex and its use for contrast media backward integration?
p. 16
“No, this is only for backward integrated product, which goes into the intermediate what we make.”
VK Singh, page 16 of the filed PDF · View the filing
Management confirmed the capex guidance remains similar at the company level.
Answered by Ganesh Karuppannan
Asked by Amlan Das: Does the company maintain its FY27 capex guidance of INR400 crores?
p. 16
“At the company level, it will be similar amount.”
Ganesh Karuppannan, page 16 of the filed PDF · View the filing
Risks flagged
Transit delays due to container non-availability and geopolitical situation affecting revenue recognition
p. 6
“During this quarter, there were transit delays due to non-availability of containers and longer transit time due to current geopolitical situation.”
Ganesh Karuppannan, page 6 of the filed PDF · View the filing
Uncertain and difficult-to-forecast raw material price trends due to geopolitical situation
p. 6
“Given the current geopolitical situation, raw material pricing trend will be uncertain in the period to come, and it will be difficult to forecast the impact in the current scenario.”
Ganesh Karuppannan, page 6 of the filed PDF · View the filing
Raw material price increases partially impacting gross margin
p. 7
“This reduction is partially through raw material price increase and due to product mix.”
Ganesh Karuppannan, page 7 of the filed PDF · View the filing
Threats from new pharmaceutical entrants in the molecule's therapeutic space
p. 13
“while we can always debate on threats from new entrants but then that's a reality of the pharmaceutical world”
VK Singh, page 13 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.